Germline Modification Carries Risk of Major Social Harm
By Marcy Darnovsky,
Nature
| 06. 04. 2008
Your Editorial 'New sources of sex cells' (Nature 452, 913; 2008), on the potential use of pluripotent stem-cell-derived gametes (PSCDGs) for germline genetic modification and enhancement, suggests that the prospect of stem-cell-derived gametes could trigger renewed calls for regulating human biotechnologies. In those discussions we must, as you warn, be wary of impeding basic research. But we must be equally willing to draw lines proscribing socially pernicious applications.
Germline (that is, inheritable) modification is the most socially consequential and ethically dubious application of human biotechnology; its implications have been explored from a wide range of perspectives. Most of these discussions have focused on the social meaning and repercussions of genetic manipulation of the human species, not on the moral status of human embryos. One can strongly support human-embryo research and still oppose germline modification. Conversely, some opponents of abortion rights support germline modification, so long as no embryos are destroyed in the process.
Although there may be scientific and therapeutic benefits from research on PSCDGs, the case for any such benefits from using these cells for human germline modification is...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...